Sava Infond d.o.o. Sells 1,200 Shares of Zoetis Inc. (NYSE:ZTS)

Sava Infond d.o.o. reduced its stake in shares of Zoetis Inc. (NYSE:ZTS) by 9.9% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,950 shares of the company’s stock after selling 1,200 shares during the quarter. Sava Infond d.o.o.’s holdings in Zoetis were worth $1,803,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Rakuten Securities Inc. lifted its holdings in Zoetis by 5,533.3% in the fourth quarter. Rakuten Securities Inc. now owns 169 shares of the company’s stock valued at $28,000 after buying an additional 166 shares during the period. Navigoe LLC acquired a new position in Zoetis in the fourth quarter valued at approximately $30,000. Murphy & Mullick Capital Management Corp acquired a new position in Zoetis in the fourth quarter valued at approximately $44,000. Sound Income Strategies LLC lifted its holdings in Zoetis by 141.4% in the first quarter. Sound Income Strategies LLC now owns 280 shares of the company’s stock valued at $46,000 after buying an additional 164 shares during the period. Finally, Bfsg LLC lifted its holdings in Zoetis by 614.6% in the first quarter. Bfsg LLC now owns 293 shares of the company’s stock valued at $48,000 after buying an additional 252 shares during the period. 92.80% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, EVP Roxanne Lagano sold 652 shares of the firm’s stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total transaction of $110,840.00. Following the sale, the executive vice president now directly owns 15,129 shares in the company, valued at $2,571,930. This trade represents a 4.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.16% of the stock is currently owned by company insiders.

Zoetis Trading Up 0.2%

ZTS opened at $157.51 on Tuesday. The firm’s fifty day moving average is $159.72 and its two-hundred day moving average is $163.10. The company has a debt-to-equity ratio of 1.12, a quick ratio of 1.04 and a current ratio of 1.74. The firm has a market cap of $70.13 billion, a PE ratio of 28.28, a price-to-earnings-growth ratio of 2.61 and a beta of 0.94. Zoetis Inc. has a twelve month low of $139.70 and a twelve month high of $200.33.

Zoetis (NYSE:ZTS) last posted its earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.08. Zoetis had a net margin of 27.12% and a return on equity of 55.48%. The company had revenue of $2.22 billion for the quarter, compared to analyst estimates of $2.20 billion. During the same period last year, the business posted $1.38 earnings per share. The business’s revenue for the quarter was up 1.4% compared to the same quarter last year. Equities research analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Friday, July 18th will be issued a dividend of $0.50 per share. The ex-dividend date of this dividend is Friday, July 18th. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.27%. Zoetis’s payout ratio is 35.91%.

Analyst Upgrades and Downgrades

ZTS has been the topic of several analyst reports. UBS Group cut their price objective on shares of Zoetis from $189.00 to $170.00 and set a “neutral” rating on the stock in a report on Wednesday, May 7th. Wall Street Zen upgraded shares of Zoetis from a “hold” rating to a “buy” rating in a report on Friday, March 7th. Stifel Nicolaus lowered shares of Zoetis from a “buy” rating to a “hold” rating and cut their price objective for the company from $165.00 to $160.00 in a report on Wednesday, June 18th. Finally, Piper Sandler increased their price objective on shares of Zoetis from $205.00 to $210.00 and gave the company an “overweight” rating in a report on Monday, May 12th. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $212.13.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.